Enzo Biochem, Inc.

    Jurisdiction
    United States
    LEI
    5299001N23WBO4XQ2P60
    ISIN
    US2941001024 (ENZ)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    InsiderPie Expert Score
    48 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. Read full profile

    Fundamentals

    Net revenue
    €23.43M
    Gross margin
    43.8%
    EBIT
    -€9.15M
    EBIT margin
    -39.0%
    Net income
    -€17.98M
    Net margin
    -76.7%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.10
    Ex date
    Payment date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 2.1M $770.43K -285K Sell

    Earnings Calls

    Latest earnings call: December 13, 2022 (Q1 2023)

    Add to watchlist

    Notifications